J&J and Contineum’s Depression Drug Missed Phase 2 Goal. What Comes Next?
Contineum Therapeutics, Inc. (NASDAQ:CTNM) has received the result biotech investors never want to see: one of its partnered drugs missed the primary endpoint of a Phase 2 trial.
